Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the MK2 Inhibitor ATI-450 in Healthy Subjects: A Placebo-Controlled, Randomized Phase 1 Study

Overview

Journal Clin Pharmacol

Publisher Dove Medical Press

Specialty Pharmacology

Date 2021 Jun 18

PMID 34140814

Citations 9

Authors

David Gordon

Edward T Hellriegel

Heidi Rath Hope

David Burt

Joseph B Monahan

Affiliations

Soon will be listed here.

Abstract

Purpose: ATI-450 is an oral, small-molecule inhibitor of the p38α mitogen-activated protein kinase (MAPK)/MAPK-activated protein kinase 2 (MK2) inflammatory signaling pathway. This phase 1, single and multiple ascending dose (SAD, MAD) study evaluated ATI-450 safety, tolerability, pharmacokinetics, and pharmacodynamics.

Patients And Methods: Healthy adults were randomly assigned to SAD (10, 30, 50, 100 mg; n=24) and MAD (10, 30, 50 mg twice daily [BID] for 7 days; n=24) cohorts of ATI-450 or placebo (n=14). Safety and tolerability were evaluated through clinical and laboratory assessments. Pharmacokinetic parameters were evaluated in plasma samples; pharmacodynamic assessments included quantification of cytokine levels (tumor necrosis factor α [TNF-α], interleukin [IL]-1β, IL-6, IL-8) and phosphorylation of the MK2 downstream substrate, heat shock protein 27 (p-HSP27).

Results: The most common adverse events were headache (10/48, 20.8%), dizziness (6/48, 12.5%), upper respiratory tract infection (3/48, 6.3%), and constipation (3/48, 6.3%). Pharmacokinetics were dose-proportional, with a terminal half-life of 9‒12 hours in the MAD cohorts on day 7. Dose- and concentration-dependent inhibition of ex vivo stimulated cytokines and target biomarker was observed. On day 7, patients in the 50 mg BID dose cohort recorded mean trough drug levels that were 1.4, 2.2, 2.3, and 2.4 times greater than the IC for TNF-α, IL-1β, IL-8, and p-HSP27, respectively. Mean C was 3.5, 5.4, 5.6, and 6.0 times greater than the IC for TNF-α, IL-1β, IL-8, and p-HSP27, respectively. IL-6 inhibition >50% was noted for part of the dosing interval.

Conclusion: ATI-450 was well tolerated at the doses investigated, exhibited dose- and time-independent (ie, linear) pharmacokinetics, and dose-related pharmacodynamic effects. These results support further study of ATI-450 in immunoinflammatory diseases in phase 2 trials.

Citing Articles

Integrative pathway analysis across humans and 3D cellular models identifies the p38 MAPK-MK2 axis as a therapeutic target for Alzheimer's disease.

Yeganeh P, Kwak S, Jorfi M, Koler K, Kalatturu T, von Maydell D Neuron. 2024; 113(2):205-224.e8.

PMID: 39610246 PMC: 11757051. DOI: 10.1016/j.neuron.2024.10.029.

Remodeling tumor-associated macrophage for anti-cancer effects by rational design of irreversible inhibition of mitogen-activated protein kinase-activated protein kinase 2.

Wang D, Sun D, Wang X, Peng X, Ji Y, Tang L MedComm (2020). 2024; 5(7):e634.

PMID: 38988492 PMC: 11233931. DOI: 10.1002/mco2.634.

Revisiting p38 Mitogen-Activated Protein Kinases (MAPK) in Inflammatory Arthritis: A Narrative of the Emergence of MAPK-Activated Protein Kinase Inhibitors (MK2i).

Ganguly P, Macleod T, Wong C, Harland M, McGonagle D Pharmaceuticals (Basel). 2023; 16(9).

PMID: 37765094 PMC: 10537904. DOI: 10.3390/ph16091286.

Emerging Treatments and the Clinical Trial Landscape for Hidradenitis Suppurativa Part I: Topical and Systemic Medical Therapies.

Fragoso N, Masson R, Gillenwater T, Shi V, Hsiao J Dermatol Ther (Heidelb). 2023; 13(8):1661-1697.

PMID: 37402031 PMC: 10366071. DOI: 10.1007/s13555-023-00956-6.

Selective Inhibition of the MK2 Pathway: Data From a Phase IIa Randomized Clinical Trial in Rheumatoid Arthritis.

Gordon D, Kivitz A, Singhal A, Burt D, Bangs M, Huff E ACR Open Rheumatol. 2023; 5(2):63-70.

PMID: 36604812 PMC: 9926068. DOI: 10.1002/acr2.11517.

References

Murali B, Ren Q, Luo X, Faget D, Wang C, Johnson R . Inhibition of the Stromal p38MAPK/MK2 Pathway Limits Breast Cancer Metastases and Chemotherapy-Induced Bone Loss. Cancer Res. 2018; 78(19):5618-5630. PMC: 6168362. DOI: 10.1158/0008-5472.CAN-18-0234. View

Damjanov N, Kauffman R, Spencer-Green G . Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum. 2009; 60(5):1232-41. DOI: 10.1002/art.24485. View

Waugh D, Wilson C . The interleukin-8 pathway in cancer. Clin Cancer Res. 2008; 14(21):6735-41. DOI: 10.1158/1078-0432.CCR-07-4843. View

Singh R, Najmi A, Dastidar S . Biological functions and role of mitogen-activated protein kinase activated protein kinase 2 (MK2) in inflammatory diseases. Pharmacol Rep. 2017; 69(4):746-756. DOI: 10.1016/j.pharep.2017.03.023. View

Ma W, Lim W, Gee K, Aucoin S, Nandan D, Kozlowski M . The p38 mitogen-activated kinase pathway regulates the human interleukin-10 promoter via the activation of Sp1 transcription factor in lipopolysaccharide-stimulated human macrophages. J Biol Chem. 2001; 276(17):13664-74. DOI: 10.1074/jbc.M011157200. View

Chrestensen C, Schroeder M, Shabanowitz J, Hunt D, Pelo J, Worthington M . MAPKAP kinase 2 phosphorylates tristetraprolin on in vivo sites including Ser178, a site required for 14-3-3 binding. J Biol Chem. 2003; 279(11):10176-84. DOI: 10.1074/jbc.M310486200. View

Schett G, Zwerina J, Firestein G . The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis. Ann Rheum Dis. 2007; 67(7):909-16. PMC: 2754165. DOI: 10.1136/ard.2007.074278. View

Muniyappa H, Das K . Activation of c-Jun N-terminal kinase (JNK) by widely used specific p38 MAPK inhibitors SB202190 and SB203580: a MLK-3-MKK7-dependent mechanism. Cell Signal. 2008; 20(4):675-83. PMC: 2423944. DOI: 10.1016/j.cellsig.2007.12.003. View

Murphy C, McGurk M, Pettigrew J, Santinelli A, Mazzucchelli R, Johnston P . Nonapical and cytoplasmic expression of interleukin-8, CXCR1, and CXCR2 correlates with cell proliferation and microvessel density in prostate cancer. Clin Cancer Res. 2005; 11(11):4117-27. DOI: 10.1158/1078-0432.CCR-04-1518. View

10.

Mahtani K, Brook M, Dean J, Sully G, Saklatvala J, Clark A . Mitogen-activated protein kinase p38 controls the expression and posttranslational modification of tristetraprolin, a regulator of tumor necrosis factor alpha mRNA stability. Mol Cell Biol. 2001; 21(19):6461-9. PMC: 99793. DOI: 10.1128/MCB.21.9.6461-6469.2001. View

11.

Jones D, Jenney A, Joughin B, Sorger P, Lauffenburger D . Inflammatory but not mitogenic contexts prime synovial fibroblasts for compensatory signaling responses to p38 inhibition. Sci Signal. 2018; 11(520). PMC: 5978689. DOI: 10.1126/scisignal.aal1601. View

12.

Hammaker D, Firestein G . "Go upstream, young man": lessons learned from the p38 saga. Ann Rheum Dis. 2009; 69 Suppl 1:i77-82. PMC: 2911016. DOI: 10.1136/ard.2009.119479. View

13.

Rokosz L, Beasley J, Carroll C, Lin T, Zhao J, Appell K . Kinase inhibitors as drugs for chronic inflammatory and immunological diseases: progress and challenges. Expert Opin Ther Targets. 2008; 12(7):883-903. DOI: 10.1517/14728222.12.7.883. View

14.

De Buck S, Hueber W, Vitaliti A, Straube F, Emotte C, Bruin G . Population PK-PD Model for Tolerance Evaluation to the p38 MAP Kinase Inhibitor BCT197. CPT Pharmacometrics Syst Pharmacol. 2016; 4(12):691-700. PMC: 4759708. DOI: 10.1002/psp4.12037. View

15.

Hitti E, Iakovleva T, Brook M, Deppenmeier S, Gruber A, Radzioch D . Mitogen-activated protein kinase-activated protein kinase 2 regulates tumor necrosis factor mRNA stability and translation mainly by altering tristetraprolin expression, stability, and binding to adenine/uridine-rich element. Mol Cell Biol. 2006; 26(6):2399-407. PMC: 1430282. DOI: 10.1128/MCB.26.6.2399-2407.2006. View

16.

Saklatvala J . The p38 MAP kinase pathway as a therapeutic target in inflammatory disease. Curr Opin Pharmacol. 2004; 4(4):372-7. DOI: 10.1016/j.coph.2004.03.009. View

17.

Wang C, Hockerman S, Jacobsen E, Alippe Y, Selness S, Hope H . Selective inhibition of the p38α MAPK-MK2 axis inhibits inflammatory cues including inflammasome priming signals. J Exp Med. 2018; 215(5):1315-1325. PMC: 5940269. DOI: 10.1084/jem.20172063. View

18.

Kotlyarov A, Neininger A, Schubert C, Eckert R, Birchmeier C, Volk H . MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis. Nat Cell Biol. 1999; 1(2):94-7. DOI: 10.1038/10061. View

19.

Fiore M, Forli S, Manetti F . Targeting Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MAPKAPK2, MK2): Medicinal Chemistry Efforts To Lead Small Molecule Inhibitors to Clinical Trials. J Med Chem. 2015; 59(8):3609-34. PMC: 4850115. DOI: 10.1021/acs.jmedchem.5b01457. View